EyeGate Announces $10.75M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with aEyeGate Pharmaceuticals, Inc.